Tonight we sit with the cherished memories of a truly unforgettable individual who changed the lives of so many fighting cancer. Tomorrow we stand and get back to the fight against the terrible disease that took one of our best, brightest, and kindest. Love you forever, Felix.

We are happy to share our work led by @AramLyu and Zenghua Fan on why prostate cancer is so resistant to immunotherapy. https://t.co/QIujWAbUTy

Can oligometastatic prostate cancer be cured with ‘total therapy’? Check out our paper reporting on outcomes after fixed-duration ADT +/- ARPI, met-directed therapy and local therapy (if de novo) for omHSPC, published in @EurUrolOncol: https://t.co/AIGJppbfWM

Honored to be among 12 outstanding oncology leaders on the @ASCO Election ballot! Make your voice heard in shaping our society's future - vote now at https://t.co/GgQ9zyoR5P. Every ballot strengthens our mission to advance cancer care.

It was such an honor giving the Felix Feng Lecture at the #pcfretreat24 on Friendship and Science. Thank you Felix for all your contributions to the field and for being an amazing friend. The love for you in the room was just palpable @PCF_Science

We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years! (Historical data <5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024

PSMAfore published @TheLancet today. Proud to have contributed to this impactful study. 50-day 🔗 to full-article: https://t.co/wZIrFnimv2

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 @NEJM

Our poster #ESMO2024 (1646P): ADT + Doce + Nivo in pts with DDR-proficient & immune-cold mHSPC did not meet PSA endpoint; 3/20 pts with durable responses; post-ADT baseline CTCs indicate persistent AR signaling as resistance mechanism. Biomarker ➕ cohorts results to follow.

Huge congrats to @apolo_andrea @sonpavde @DrRosenbergMSK @WilliamKimMD @bergsa83 & the @ALLIANCE_org team on a terrific @myESMO presentation & a concomitant @NEJM paper! A very exciting #ESMO24 indeed!

Terrific overview of BiTEs in #prostatecancer at #ESMO24 by @neerajaiims @huntsmancancer. #PSMA, #STEAP1, #DLL3 & other targets being exploited with varying levels of success. BEAUTIFUL comprehensive tables included in his talk that give immediate perspective of the status of

Standing room only for #ESMO24 prostate session, @mishabeltran excellent discussions on DLL3 targeting in neuroendocrine prostate cancer and @neerajaiims on T-cell engagers

Masterful discussion by @VincentWenxinXu of the biomarker data presented, including the KIM-1 data to which he has personally had very important contributions. @ASCO #ASCO24

What an incredible way to spend last Saturday - surrounded by the brightest minds in the field and more importantly, the brightest lights in my life. Thank you all for coming out and attending the #FengSymposium! I am so grateful for you all 🙏🏼

To my amazing brother-(in law): visionary scientist, incredible mentor, loving husband and father - ❤️❤️❤️ He’s lifted up so many. So fitting for a YIA to be dedicated to him and moving to see such an outpouring of support - Please donate if you can …

1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. https://t.co/8hGQjmqZr6

Noninvasive detection of NEPC by targeted cfDNA methylation @CD_AACR co-led by @FrancescaBZNY and her lab @UniTrento. Congrats to first author @GMFranceschini and thank you to many amazing collaborators @PCF_Science @DanaFarber_GU #NEMO https://t.co/rToG0QfXB1

Excited to share our latest work: “liquid biopsy epigenomic profiling for cancer subtyping”, JUST IN @NatureMedicine https://t.co/cwM0MpCrhX

⁦@ChrisSweens1⁩ giving an excellent discussion on placing PSMAFore data in context. ⁦@thomashopemd⁩ ⁦@alantanmd⁩ ⁦@DrChoueiri⁩ ⁦@morr316⁩ #ESMO2023

The erudite @sartor_oliver w/ the long awaited #PSMAfore data comparing #PSMALu vs abi/enza for met #prostatecancer pre-chemo. Improved rPFS & trending toward OS benefit despite planned x-over. Dry mouth most bothersome — less AEs overall for Lu than for ARTA. #ESMO23 @OncoAlert